Tirzepatide
Research highlights
- ✓Dual GLP-1 and GIP receptor activation in a single compound
- ✓Extensively studied — one of the most referenced metabolic peptides
- ✓May support appetite-regulation, insulin-sensitivity & body-composition research
- ✓Excellent value at the highest dose format
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It became the benchmark metabolic peptide following landmark trials studied against semaglutide.
What purity is guaranteed?
Where we hold an independent Janoshik report for a compound we publish it in full - batch number, purity and a verification key you can check against the lab yourself. Where we do not hold one the product is marked research grade and we say so, rather than claim a report we cannot produce.
How do I order?
Click the WhatsApp button, tell us what you need, and we'll handle the rest — payment details, shipping, and tracking.
Tirzepatide, explained
The short version: Tirzepatide is one peptide that switches on two hormone receptors, GIP and GLP-1. It is the active ingredient in Eli Lilly's Mounjaro and Zepbound, and the compound that made "dual agonist" a phrase people actually search for.
What it is
Tirzepatide is a chain of 39 amino acids. Its backbone is modelled on GIP, a hormone your gut releases after a meal, and it has been tweaked so it also activates the GLP-1 receptor. A fatty-acid tail lets it ride on albumin, a protein in the blood, which is why it lasts about five days instead of a few minutes.
Why two receptors
GIP and GLP-1 are both incretins: gut hormones that tell the pancreas to release insulin when there is food around. The first wave of compounds, semaglutide included, only target GLP-1. Tirzepatide adds GIP on top.
Exactly why adding GIP helps is still being worked out. Researchers are looking at its effects on fat tissue and on how well the GLP-1 side is tolerated. What is not in doubt is that the combination produced bigger numbers in trials than GLP-1 alone.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Approved medicine | Yes: Ozempic, Wegovy | Yes: Mounjaro, Zepbound | Not yet: phase 3 passed in 2026, filing planned for 2027 |
What the big trials found
SURMOUNT-1 (New England Journal of Medicine, 2022) followed 2,539 adults with obesity or overweight, without diabetes, for 72 weeks. Average body weight fell by between 15% and 21% across the three doses tested, against 3.1% on placebo.
On the strength of trials like this, the US FDA approved tirzepatide as Mounjaro for type 2 diabetes on 13 May 2022, and as Zepbound for chronic weight management on 8 November 2023.
Where the evidence stops
Those results come from pharmaceutical-grade drug, given under medical supervision, to carefully chosen people. Research-grade material is not that product, and none of the trial numbers tell you what it will do outside a trial.
The effects reported most often in the trials were gut-related: nausea, diarrhoea and constipation, usually early on.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water is added, it belongs in the fridge and the clock starts. Our reconstitution and storage guide covers the details, and the calculator does the maths.
Two receptors, one molecule, and some of the strongest trial data of anything we stock. Read it as research, not a promise.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Tirzepatide
No reviews from orders with Tirzepatide yet. Here is what recent customers said about ordering from us.
★★★★★
Great service as always
Nico V. · 6 Oct 2026
★★★★★
I am happy with my product
Kholofelo L. · 30 Sep 2026
★★★★
Small checkout glitch, but after following up it was quickly sorted out and everything went smoothly from there. Good customer service - thank you.
Tonia K. · 30 Sep 2026
★ 4.8 across all 16 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
